This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract does not include a full text component.
Phase I dose-escalation study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors.
Central nervous system (CNS) outcomes and progression patterns in patients with RET fusion-positive lung cancers treated with selpercatinib. This is an ASCO Meeting Abstract from the 2022 ASCO Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results